Executive Director, Asset Strategy Leadership

About the role

The Executive Director, Asset Strategy Leadership will drive the strategic positioning of Recursion’s clinical assets, ensuring decision-making is grounded in competitive reality, differentiated by Recursion OS insights, and executed with urgency for patient benefit. You will leverage advanced computational approaches and proprietary Recursion OS/ClinTech advantages across the portfolio, redefining traditional drug development paradigms. This role partners with preclinical, clinical, and platform teams to promote alignment, optimize processes, and deliver transformative medicines.

Responsibilities

• Define and drive asset strategy for small molecule clinical programs in oncology and immunology/inflammation, integrating competitive positioning, mechanistic differentiation, biomarker strategy, and patient segmentation to inform go/no-go and prioritization decisions.
• Translate Recursion OS and ClinTech insights into strategic asset advantages, ensuring proprietary data and computational insights maximize portfolio advancement.
• Develop and pressure-test competitive narratives for each oncology and immunology/inflammation portfolio asset, building evidence to inform leadership decisions, partnering discussions, and investor communications.
• Partner with functional leaders across clinical development, BD, finance, and platform teams to align resource allocation with strategic priorities.
• Propagate Recursion’s mission of radically changing lives by raising the bar on how assets are advanced, differentiated, and delivered to patients with significant unmet need.

Requirements

• PhD in life sciences or related scientific discipline with deep expertise in drug discovery and development.
• 10+ years of biotech/pharma experience with a proven track record of asset-level strategic leadership, advancing programs through clinical stage-gates with demonstrable impact on portfolio value.
• Deep expertise in small molecule therapeutics for oncology and immunology/inflammation; rare disease experience a bonus.
• Experience leveraging computational approaches and data-driven platforms to sharpen asset strategy and clinical decision-making.
• Proven ability to build and articulate strategic and competitive cases for clinical assets, integrating mechanistic differentiation, competitive dynamics, regulatory, and market considerations.
• Strong financial acumen; able to engage credibly on cross-functional resourcing, asset valuation, and portfolio trade-offs.
• Exceptional executive presence, synthesizing complexity into clear, conviction-led recommendations for senior leadership and external partners.

About the Team

The Portfolio Team is execution-minded and analytically rigorous, fluent in both science and AI, and responsible for industrializing Recursion’s innovative science to advance impactful medicines. This role operates as a senior strategic partner to leaders in Clinical Development, Discovery, ClinTech, Platform, and BD, breaking traditional silos to optimize asset positioning for patient benefit.

Benefits

• Annual base salary range: $297,000–$356,400.
• Eligibility for annual bonus and equity compensation.
• Comprehensive benefits package.

Schedule

This is an office-based, hybrid role in New York City. Employees are expected to work in the office at least 50% of the time.

Values

• Act boldly with integrity: Unconstrained thinking, calculated risks, and ethical decision-making.
• Care deeply and engage directly: Responsibility, respect, and honest communication.
• Learn actively and adapt rapidly: Progress through experimentation, testing, and refinement.
• Move with urgency: Daily progress driven by purpose, not rushing.
• Take ownership and accountability: Leaders drive decisive action; teams own outcomes together.
• One Recursion: Cross-functional collaboration built on trust, clarity, humility, and impact.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. The company advances a portfolio of investigational medicines in oncology, rare disease, neuroscience, immunology, and other areas with significant unmet need. Recursion OS, an AI-native drug discovery and development platform, integrates biology, chemistry, and clinical development into a unified intelligence system powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI. Recursion’s infrastructure is based in Salt Lake City, Utah, and Milton Park, Oxfordshire, with additional offices in New York, Montréal, and London.